192 related articles for article (PubMed ID: 22569849)
1. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
Strecker K; Adamaszek M; Ohm S; Wegner F; Beck J; Schwarz J
J Neural Transm (Vienna); 2012 Nov; 119(11):1351-9. PubMed ID: 22569849
[TBL] [Abstract][Full Text] [Related]
2. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Kovoor A; Seyffarth P; Ebert J; Barghshoon S; Chen CK; Schwarz S; Axelrod JD; Cheyette BN; Simon MI; Lester HA; Schwarz J
J Neurosci; 2005 Feb; 25(8):2157-65. PubMed ID: 15728856
[TBL] [Abstract][Full Text] [Related]
3. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
[TBL] [Abstract][Full Text] [Related]
4. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Paquette MA; Foley K; Brudney EG; Meshul CK; Johnson SW; Berger SP
Psychopharmacology (Berl); 2009 Jul; 204(4):743-54. PubMed ID: 19283364
[TBL] [Abstract][Full Text] [Related]
5. Adaptive gene regulation in the Striatum of RGS9-deficient mice.
Busse K; Strotmann R; Strecker K; Wegner F; Devanathan V; Gohla A; Schöneberg T; Schwarz J
PLoS One; 2014; 9(3):e92605. PubMed ID: 24663062
[TBL] [Abstract][Full Text] [Related]
6. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
7. Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Beck J; Riederer P; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1727-32. PubMed ID: 21274579
[TBL] [Abstract][Full Text] [Related]
8. 5-HT
Al-Kassmy J; Sun C; Huot P
Neurodegener Dis Manag; 2023 Apr; 13(2):101-112. PubMed ID: 37140165
[TBL] [Abstract][Full Text] [Related]
9. Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain.
Marazziti D; Palego L; Giromella A; Mazzoni MR; Borsini F; Mayer N; Naccarato AG; Lucacchini A; Cassano GB
Int J Neuropsychopharmacol; 2002 Jun; 5(2):131-40. PubMed ID: 12135537
[TBL] [Abstract][Full Text] [Related]
10. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Sagarduy A; Llorente J; Miguelez C; Morera-Herreras T; Ruiz-Ortega JA; Ugedo L
Exp Neurol; 2016 Mar; 277():35-45. PubMed ID: 26687972
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
[TBL] [Abstract][Full Text] [Related]
12. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Zhao R; Lu W; Fang X; Guo L; Yang Z; Ye N; Zhao J; Liu Z; Jia J; Zheng L; Zhao B; Zhang A; Zhen X
Pharmacol Biochem Behav; 2014 Sep; 124():204-10. PubMed ID: 24955866
[TBL] [Abstract][Full Text] [Related]
13. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Ba M; Kong M; Ma G; Yang H; Lu G; Chen S; Liu Z
Brain Res; 2007 Jan; 1127(1):177-84. PubMed ID: 17113046
[TBL] [Abstract][Full Text] [Related]
14. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
16. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
17. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Garcia J; Winkler C; Björklund A; Carta M
Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
[TBL] [Abstract][Full Text] [Related]
18. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
19. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
20. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]